ORIGINAL PROF-3091 ABSTRACT… Introduction: Different pathogen reducing technologies are being implemented which includes S-303. CD-61 is important receptor for clotting. Pathogen reducing agents are being studied extensively to probe its effects. Objective: We conducted this study to review the docking of S-303 at CD-61, to look into the effect of S-303 on function of platelets. Study Design: This was an observational study. Setting: In-silico study. Period: March 2015 to August 2015. Method: The study was carried out in-silico. PDB (Protein data bank) code of Tirofiban bound to CD-61 was 2vdm. CD-61 was docked with Tirofiban using online docking tools i.e. Patchdock and Firedock. Then, S-303 and CD-61 were also docked. Best docking poses to active sites of 2vdm were found. Interactions of ligands and CD-61 were obtained. Then comparison of Hydrogen Bonds, Hydrogen Bond Lengths, Hydrophobic bonds of 2vdm molecule and best poses of docking results were done. Patchdock and Firdock results of best poses were also analyzed using SPSS-16. Results: The Hydrogen bonds and Hydrogen bond length and hydrophobic bonds of docking results were compared to 2vdm. 2 best poses were obtained for docking of tirofiban to CD-61. No docking to active site was observed in Patchdock and firedock for S-303to CD-61. Conclusion: S-303 did not bind to the active site of CD-61. We can assume that S-303 does not affect this important receptor of platelet which is needed for proper function of platelets.
Objective: To Estimate the frequency of blood group discrepancies among Leukemia Children. Study Design: Cross Sectional study. Setting: University of Child Health Sciences, The Children Hospital Lahore. Period: October to January 2020. Material & Methods: This study was conducted among patients in CH and ICH Lahore, regarding ABO blood group discrepancies in leukemic patients, in the year 2019. A total of 200 samples were processed in order to detect ABO blood group discrepancies by tube method of blood grouping, using antisera-A, antisera-B, antisera-D for forward grouping and A-cells, B-cells and O-cells for reverse grouping. Auto-control was also run by reacting patient’s cell suspension with the patient’s own serum. The collected data were checked for its completeness, consistency and accuracy before analysis. Results: In this study, a total of 200 subjects were included out of which 122 (61%) were male patients and 78 (39 %) were female. Most common age group was 6-10 years. ALL 157(78.5%) and AML 43(21.5%). Blood group discrepancy was found in 5 (2.5%) and all were of Group I. Conclusion: The study found that leukemia (ALL, AML) results in ABO discrepancies that must be resolved by proper serological workup. Both forward and reverse grouping should be performed to investigate the correct ABO blood group in leukemic patients and accurately matched blood must be transfused to these patients.
Transfusion of blood products is one of the key aspects of hospital care. Amongthe risk of blood transfusions, bacterial contamination of the blood bags is not so uncommon.Sources of bacteria can be several. Majority of the times the source of bacteria is the arm of thedonor. Second important cause of bacterial contamination of blood transfusion, is bacteria inthe blood stream of the donor. Donor is usually selected with strict selection criteria. Detailedhistory is usually taken. Diversion is another method used to reduce the bacterial contaminationof blood bags. Temperature is also important parameter for the growth of bacteria. RBCs arestored at 4 ˚C and platelets are stored at 22˚C. For the ideal bacterial detection techniques,it is important that they can detect the bacteria as early and as low as possible. At the time ofcollection of sample for viral screening, number of bacteria might be too low to be detected.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.